First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation …
K Park, CJ Yu, SW Kim, MC Lin, V Sriuranpong… - JAMA …, 2016 - jamanetwork.com
Importance Continuing molecularly targeted treatment beyond disease progression in non–
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
[HTML][HTML] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori, T Hida… - Lung Cancer, 2013 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
[HTML][HTML] First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III …
Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm …
R Rosell, U Dafni, E Felip… - The Lancet …, 2017 - thelancet.com
Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …
R Rosell, E Carcereny, R Gervais… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
[HTML][HTML] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - Lung Cancer, 2021 - Elsevier
Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto, S Atagi… - The lancet …, 2014 - thelancet.com
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - 2018 - ascopubs.org
9007 Background: In JO25567 (Clinical trials registry number. JapicCTI-111390), EB
significantly prolonged progression-free survival (PFS) in patients with NSCLC with …
significantly prolonged progression-free survival (PFS) in patients with NSCLC with …